OTC · ALSE
Alseres Pharmaceuticals, Inc.
Healthcare · Biotechnology
$0.01
Up+$0.01 (+100.00%)
Updated Aug 18, 2026, 3:49 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 398.26K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 66
- Avg. volume
- 0
Price performance
ALSE price history
1M range · 0 trading sessions · Daily adjusted prices
ALSE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ALSE news
The latest Smart Investors Daily articles mentioning ALSE.
Stock researchCompany · Overview
ALSE research
Overview
Company profile and research snapshot.
Company profile
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
